The Central Role of the Gut Microbiota in Chronic Inflammatory Diseases by Ferreira, Caroline Marcantonio et al.
Review Article
The Central Role of the Gut Microbiota in
Chronic Inflammatory Diseases
Caroline Marcantonio Ferreira,1 Angélica Thomaz Vieira,2 Marco Aurelio Ramirez Vinolo,3
Fernando A. Oliveira,4 Rui Curi,5 and Flaviano dos Santos Martins6
1 Department of Pharmacology, Institute of Biomedical Sciences, ICB-1, Sao Paulo University, 05508-000 Sa˜o Paulo, SP, Brazil
2 Department of Genetics, Institute of Biological Sciences, Federal University of Minas Gerais, 31270-901 Belo Horizonte, MG, Brazil
3 Department of Genetics, Evolution and Bioagents, Institute of Biology, University of Campinas, 13083-970 Campinas, SP, Brazil
4Department of Biological Sciences, Section of Physiology and Pharmacology, Federal University of Sao Paulo,
09913-030 Diadema, SP, Brazil
5 Department of Physiology and Biophysics, Institute of Biomedical Sciences, ICB-1, Sao Paulo University,
05508-000 Sa˜o Paulo, SP, Brazil
6Department of Microbiology, Institute of Biological Sciences, Federal University of Minas Gerais,
31270-901 Belo Horizonte, MG, Brazil
Correspondence should be addressed to Caroline Marcantonio Ferreira; caro valpa@hotmail.com
Received 16 July 2014; Accepted 28 August 2014; Published 18 September 2014
Academic Editor: Borja Sa´nchez
Copyright © 2014 Caroline Marcantonio Ferreira et al. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
The commensal microbiota is in constant interaction with the immune system, teaching immune cells to respond to antigens.
Studies inmice have demonstrated thatmanipulation of the intestinalmicrobiota alters host immune cell homeostasis. Additionally,
metagenomic-sequencing analysis has revealed alterations in intestinal microbiota in patients suffering from inflammatory bowel
disease, asthma, and obesity. Perturbations in the microbiota composition result in a deficient immune response and impaired
tolerance to commensal microorganisms. Due to altered microbiota composition which is associated to some inflammatory
diseases, several strategies, such as the administration of probiotics, diet, and antibiotic usage, have been utilized to prevent or
ameliorate chronic inflammatory diseases. The purpose of this review is to present and discuss recent evidence showing that the
gut microbiota controls immune system function and onset, development, and resolution of some common inflammatory diseases.
1. Introduction
Commensal microbiota consists of many microorganisms
that cover all host mucosal surfaces, but most reside in the
gastrointestinal tract, which is the subject of this review.
Amazingly, although the humanbody is composed of approx-
imately 100 trillion cells, only 10 trillion are human cells while
90 trillion are microbes. The genes of these microorganisms
form our metagenome, known as our second genome [1].
Thus, it is not surprising that this large arsenal of gene
products has a relevant role in body homeostasis [2, 3]. The
relationship between the gut microbiota and its host plays
a key role in immune system maturation, food digestion,
drug metabolism, detoxification, vitamin production, and
prevention of pathogenic bacteria adhesion [4]. One of the
most important roles of the microbiota is the maturation
of the immune system in the postnatal period. The first
appearance of adaptive immunity in humans coincides with
acquisition of a complex diet and microbiota, which suggests
that mucosal immunity in the intestines has evolved to
tolerate diverse microbes and food antigens.
Colonization of the gastrointestinal tract begins after
birth, despite the fact that some researchers have discovered
a small community of bacteria living in the placenta [5].
However, there is no convincing evidence demonstrating that
such bacteria normally reach the fetus through the placenta. It
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is known that colonization initiates frommaternally acquired
bacteria during birth [6] and breastfeeding and continues
throughout our life [7–9]. Over the lifetime of the individual,
or at least until stabilization of colonizing microbiota in
adulthood, there is a change in the profile of the predom-
inant phyla in the gastrointestinal tract, migrating from a
community dominated by Actinobacteria and Proteobacteria
to one dominated by Firmicutes and Bacteroidetes [10]. The
metagenome of an infant gut is characterized by an enrich-
ment of genes required for the breakdown of simple sugars,
such as lactose and galactose, while the weaned infant micro-
biota is enriched in genes for polysaccharide breakdown and
vitamin production [11, 12]. Most bacterial species in the
human and mouse gut belong to the phyla Bacteroidetes
and Firmicutes, but less abundant bacterial phyla, such as
Actinobacteria, Proteobacteria, and Verrucomicrobia, as well
asmethanogenic archaea,mainlyMethanobrevibacter smithii,
are also present [13, 14].
The composition of the microbiota is influenced by
environmental factors such as diet, antibiotic therapy, and
environmental exposure to microorganisms. Additionally, it
can vary according to sex, age, and geographical origin of
the individual [15]. An overgrowth of pathogenic microbial
colonies causes an imbalance known as dysbiosis. Antibiotic
therapy, alcohol misuse, and inappropriate diet are factors
that can lead to dysbiosis [16–18].
The normal relationship between the gut microbiota and
the immune system is established by bacteria, cells, and
receptors of both the innate and adaptive immune systems.
Microbes are held in the intestinal lumen through the com-
bined efforts of the epithelial barrier, mucus layer, antimi-
crobial peptides, and antibodies. Controlling the intestine’s
metabolic products is also important for themaintenance of a
mutually beneficial relationship between the microbiota and
the immune system.When this connection is broken and fails
to resolve itself, an inflammatory response is initiated.
Here, we review the mechanisms by which the gut
microbiota contributes to the development of asthma, bowel
disease, and obesity, highlighting the regulatory role of the
gut microbiota in immune system function.
2. Mechanisms Linking the Microbiota and
Its Products to the Immune System
Recently, several studies have shown possible links between
the gutmicrobiota and the immune system.Here, we summa-
rize some of the “sensors” that are involved in this interaction
and describe related pathological conditions.
Innate immune cells such as macrophages, neutrophils,
and dendritic cells, as well as other cell types including epithe-
lial cells, which form the interface between the body and
the external environment and are in close contact with the
microbiota, express several membrane and intracellular pro-
teins that sense microbial molecules. Examples of these sen-
sors include pattern-recognition receptors such as Toll-like
receptors (TLRs), C-type lectin, nucleotide oligomerization
domain (NOD) receptors (NLRs), and retinoic acid inducible
gene (RIG)-I-like receptors (RLRs), which are activated by
microbial molecules including flagellin, lipopolysaccharide,
lipoteichoic acid, peptidoglycans, N-acetylglucosamine, and
double stranded-RNA. Considering the types of ligand that
activate these receptors, it is not surprising that some par-
ticipate in the microbiotic regulation of the immune system
and serve as regulators themselves. These receptors also play
a role in shaping the microbiota. For example, in the absence
of TLR5, a receptor activated by bacterial flagellin, mice
present changes in microbiota composition that have been
associated with the development of metabolic syndrome in
these animals [19].
NLR proteins are expressed in a wide variety of both
immune and nonimmune cells and detect microbial and
endogenous signals released from these cells. These pro-
teins consist of three domains: a central nucleotide-binding
domain termed NACHT (referred to as the NOD domain)
and both amino- and carboxy-termini consisting of leucine
rich repeats (LRR domains). These latter two domains are
important, respectively, for interaction with other proteins
that initiate a signaling cascade and for recognition of
molecules that activate a family of receptors comprising
22 different human proteins. These proteins are classified
based on their N-terminal domain, which includes a caspase
recruitment domain (CARD) on Nod1, Nod2, and NLRC3,
4 and 5; a pyrin domain (PYD) on NLRP1-14; an acidic
transactivating domain on NLRA; or a baculovirus inhibitor
repeat (BIR) on NAIP [20]. Several studies have shown that
changes in the expression of these intracellular sensors lead
to modifications in the composition (both qualitative and
quantitative) of the microbiota and the immune system and
have been associated with the development of conditions
including colitis, bacterial infection, obesity, and insulin
resistance [21].
Another class of sensors that detects molecules derived
from the microbiota is the G protein-coupled receptors
(GPCRs). These receptors will be discussed in detail below.
At least three GPCRs have been identified that bind to
short chain fatty acids (SCFAs) produced by gut bacteria:
GPR41, GPR43, and GPR109A. GPR41 (i.e., FFAR3) and
GPR43 (i.e., FFAR2) are both highly expressed on immune
cells such as polymorphonuclear cells and macrophages [22].
Additionally, other cells and tissues including adipose tissue,
enteroendocrine cells and the cells of the sympathetic ner-
vous system have also been shown to express these receptors
and tomediate some of their biological effects [23]. G protein-
coupled receptors are activated by SCFA; butyrate binds to
GPR41 with high affinity, but acetate and propionate have
a greater affinity for GPR43 [24–26]. Some of the effects
associated with SCFA depend on the activation of GPR43
and include reactive oxygen species (ROS) production and
neutrophil chemotaxis. More recently, it has been shown that
via this receptor, SCFAmodulates the number of T regulatory
cells (Tregs) in the colon, an effect that will be further
described in last section of this review. GPR41 activation has
been associated with regulation of metabolism and energy
expenditure.
GPR43 is reported to activate both Gi/o and Gq, while
GPR41 signals via Gi/o only. Both receptors induce intracel-
lular calcium mobilization and inhibit cAMP accumulation.
Journal of Immunology Research 3
The MAPKs ERK1/2, JNK, and p38 are activated by SCFAs
through binding to the GPCRs [27]. GPR41 and GPR43
activation of ERK1/2 is dependent on Gi/o, because the
inhibition of this G protein by the pertussis toxin abolishes
the stimulatory effect of SCFAs on this pathway in cells
expressing only the GPR41 and reduces it in more than 50%
in cells expressing GPR43 alone [27]. In neutrophils, ERK1/2,
p38, and PKB are activated by SCFAs through a pertus-
sis toxin sensitive pathway and are important for GPR43-
dependent chemotaxis. A recent study has demonstrated a
chemotactic of SCFAs through amechanism involving PI3K𝛾
and the small G protein Rac2 [23]. Recently, it has also
been shown that SCFAs induce chemokine and cytokine
expression in colonic epithelial cells in a GPR41- and GPR43-
dependentmanner. In this study, the authors demonstrate the
involvement of Gi/o, ERK, p38, and the transcription factor
ATF2 in this SCFA-induced expression [28].
GPR109A, also known as hydroxy-carboxylic acid 2
receptor or HM74a, is a receptor for nicotinate. Additionally,
this protein binds to the ketone body 𝛽-D-hydroxybutyrate
and to the SCFA butyrate [29, 30]. This receptor is expressed
on hematopoietic-derived cells, white and brown adipocytes,
keratinocytes, colonocytes, and hepatocytes [29, 30].
3. Asthma
Asthma is a chronic airway disease characterized by excessive
contraction of airway smooth muscle (termed airway hyper-
responsiveness or AHR), exacerbated mucus production,
eosinophilia, and elevated Th2 cytokine production [31].
Asthma affects approximately 300 million people worldwide,
and it is estimated that in 2025, more than 100 million
people will be diagnosedwith this pathology [32, 33]. Current
treatment is based on anti-inflammatory therapies, which
do not cure asthma. Furthermore, AHR may persist even
in the absence of inflammation. The treatment of asthma is
complex because there are many asthma phenotypes, and its
effectiveness depends on environmental and genetic factors
[34]. Asthma prevalence is increasing in Western countries
due to lifestyle modifications including excessive hygiene
(i.e., little exposure to microbes) and use of antibiotics and
a high-fat diet [35–40]. Epidemiological studies have shown
that exposure tomicrobes early in life is a critical factor in the
induction of allergic diseases, leading to the development of
the hygiene hypothesis [35–39]. Briefly, this theory proposes
that excessive cleaning and reduced pathogen exposure leads
to an inadequate immune response [41]. Likewise, the use
of antibiotics early in life is also associated with allergic
sensitization andAHR [42].Thus, exposure tomicrobes early
on has a great influence on immune function later in life.
Moreover, the intestinal microbiota, our largest collection of
microorganisms,modulates the pathophysiological processes
of asthma. Several groups have noted that the hygiene
hypothesis should be rewritten to include the role of the
intestinal microbiota and thus renamed as the “microflora
hypothesis.” The “microflora hypothesis,” initially discussed
by Noverr and Huffnagle [43], postulates that perturbations
in the gastrointestinal microbiota, resulting from reduced
microbial exposure due to changes in diet and antibiotic use
[44], lead to an underdevelopedmicrobiota.This “immature”
microbiota delays proper maturation of the immune system.
The sequence of events that promotes the development of
immunological tolerance is disrupted, leading to allergic
hypersensitivity [43].
Epidemiologic studies have identified associations
between alterations in the composition of gut bacterial
communities and the development of allergies [45, 46].
Children with asthma have a different intestinal microbiota
compared to nonasthmatic children. Asthmatic children
have a high prevalence of certain species of Clostridium
difficile (bacterium with pathogenic characteristics) and low
Bifidobacterium (nonpathogenic bacteria) in their intestinal
microbiota [45, 47]. Clinical trials have indicated that feeding
Lactobacillus rhamnosus GG and Lactobacillus fermentum
to mothers in the prenatal and early postnatal periods may
be effective in the treatment and prevention of early atopic
disease in children [47, 48].
Studies in animal models have also shown that gut
bacteria modulate experimental asthma [22, 49]. Researchers
have employed three main strategies to interfere with gut col-
onization and showed its effects beyond the local gut immune
response. These strategies include maintaining germ-free
(GF) mice (devoid of microbiota) in a sterile environment,
microbiota depletion/perturbation by antibiotic therapy, and
alteration of the microbiota composition through modifica-
tion of the host’s diet.
The mechanisms by which the innate immune system
recognizes the commensal-derived signal that regulates Th2
inflammation is currently being studied. Dendritic cells
(DCs), basophiles, and invariant natural killer T (iNKT) cells
are part of this mechanism. DCs are the primary antigen-
presenting cells responsible for the antigen-specific activation
of naive T cells. Microbes in the intestine are sampled by
DCs either directly from the lumen or through the gut-
associated lymphoid tissue (GALT). A combination of signals
from microbes results in phenotypic changes in the DCs,
which leads to the differentiation of Th1, Th2, and Treg
cells (Figure 1). One phenotypic change is the increased
production of IL-10 by these cells. DCs expressing high levels
of IL-10 drive the generation of CD4+FOXP3 Tregs and
the establishment of tolerance. Tolerance can be established
by the activation of Th1 and Treg cells. This regulatory
mechanism plays a key role in the immunoregulatory action
of many probiotics. In this way, the intestinal microbiota may
induce Treg cells in the GALT that then spread to the airways
in response to allergen exposure. This idea is supported by
the finding that oral treatment with Lactobacillus reuteri
results in an increase in Treg cells in the draining lymph
nodes of the lung. Additionally, L. rhamnosus GG has been
shown to reduce themurine allergic airway response through
associated increases in FOXP3T cells only when bacteria are
administered in the neonatal period [50, 51]. The generation
of Treg cells is only one mechanism; other mechanisms
may also account for the effects of microbiota in immune
regulation, as discussed below.
Germ-free mice exhibited an exaggerated number of
airway eosinophils, increased production of Th2 cytokines,
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Figure 1: Schematic representation of the pulmonary allergic response induced by gastrointestinal (GI) immune cells and two microbiota-
related conditions (a healthy gut microbiota and a reduced gut microbiota following antibiotic treatment). Microbes in the intestines are
sampled by Toll-like receptors (TLRs) onDCs either directly in the lumen or in the gut-associated lymphoid tissue (GALT). In the healthy gut
microbiota, polymorphonuclear development (PMN) is normal and DCs become regulatory DCs (DCr) that promote development of Tregs
and/orTh1 cells and natural killer (NK) cells.These NK cells inhibitTh2 inflammation. Antibiotic treatment kills a large proportion of healthy
microbiota, leading to a reduced gut microbiota and an inflammatory environment without DCs, Th1 cells or NK cells. In this environment,
an unhealthymicrobiota elevates serum immunoglobulin E (IgE) levels, increases circulating basophil populations, and exacerbates basophil-
mediatedTh2 responses (adapted from Forsythe [110]).
elevated immunoglobulin E (IgE) production and an altered
number and phenotype of DCs when sensitized and chal-
lengedwith ovalbumin (OVA).This phenotypewas abolished
by recolonization of germ-free mice with the complex com-
mensal flora of specific pathogen-freemice [52]. Interestingly,
Tregs were unaffected in GF mice, although the number
of basophils was increased. Moreover, depletion or dele-
tion of bacterial communities was associated with elevated
serum IgE concentrations, an increased circulating basophil
population, exaggerated Th2 cells responses, and allergic
inflammation [53] (Figure 1). Additionally, the exaggerated
Th2 response was reduced upon depletion of basophils.
Thus, basophils are an important link between the gut
microbiota and allergic inflammation. Recently, investigators
have discovered a mechanism by which commensal bacteria
regulate basophil functions, interferingwith the susceptibility
of the Th2 immune response. They found that treatment
with oral antibiotics increased serum IgE concentrations by
increasing the level of circulating basophils and inducing an
exaggerated Th2 inflammation. B cell-intrinsic expression of
MyD88 is an important step in increasing serum IgE and
basophil levels. When expression of MyD88 is blocked by a
healthymicrobiota, there is no development of allergic airway
inflammation (Figure 1) [52].
Treg cells and basophils are not the only cell types
affected by microbiota in mouse models. GF mice contain
an increased number of iNKT cells compared to specific
pathogen free (SPF) mice [49]. iNKT cells secrete abundant
levels of IL-4, IL-12, and IFN-𝛾 upon activation, resulting in
increased susceptibility to allergic inflammation. Moreover,
greater Th2-mediated airway inflammation was observed in
GF mice than in SPF mice when mice were sensitized with
OVA. Asthma in GF mice was CD1-d dependent, because
depletion of these cells decreased allergic inflammation.
Interestingly, researchers also observed that colonization of
neonatal, but not adult, GF mice with conventional micro-
biota protected the animals from mucosal iNKT accumula-
tion and asthma [49]. Thus, microbial contact early in life is
critical for the establishment of mucosal iNKT cell tolerance
to antigens in exposed airways.
In addition to innate immune cells, other elements
related to microbiota may be important in the regulation
of Th2-mediated airway inflammation. SCFAs are the major
end products of bacterial metabolism in the human large
intestine.The fermentation of complex plant polysaccharides
leads to the production of SCFAs such as propionate, butyrate,
and acetate. As described above, SCFAs have been reported
to show anti-inflammatory properties such as leukocyte
recruitment, leukocyte chemotaxis, and chemokine produc-
tion [54, 55]. Animals deficient in a receptor coupled to
GPR43 that binds to SCFAs, including acetate, have an
exaggerated inflammatory response in models of colitis,
arthritis, and asthma. OVA-sensitized GPR43 KO mice have
a greater inflammatory infiltrate in the airways and lung
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tissue compared to littermatemice [22].Moreover, Trompette
et al. [56] found that fermentable dietary fiber content
changed the composition of mouse gut and lung microbiota
by altering the ratio of Firmicutes to Bacteroidetes bacteria,
which consequently increased the concentration of SCFAs,
specifically propionate. Mice fed a high-fiber diet were pro-
tected against allergic inflammation in the lungs by increased
DC phagocytic function, although the DCs also displayed
an impaired ability to mediate Th2 airway inflammation.
Altogether, these studies suggest that SCFAs are important in
controlling allergic pulmonary inflammation.However, there
are only a few studies showing SCFA modulation of immune
system function. The mechanism by which SCFA reduces
AHR remains unknown. All SCFAs have the same effect
on airway inflammation and lung function. The question,
of which microbiota is more important for immunological
responses in the airways, lung microbiota or gut microbiota,
remains unanswered.
As a whole, the gut microbiota has a significant effect
on airway immunity. Therefore, it is relevant to consider the
composition of the host microbiota with the same level of
importance as genetic polymorphisms and environmental
factors when diagnosing and treating asthma.
4. Inflammatory Bowel Disease
The incidences of inflammatory bowel disease have risen
rapidly over the last several years. Crohn’s disease and ulcera-
tive colitis are the main inflammatory bowel diseases (IBDs)
and are characterized by a chronic and exacerbated inflam-
mation of the intestinal mucosa [57]. In addition to genetics,
several factors contribute to the high incidence of IBDs
such as lifestyle and the intestinal microbiota. Commensal
microbiota plays an important role in the pathogenesis of
inflammatory bowel disease [58, 59] because experimental
colitis has been successfully treated with an antibacterial
agent [60] and antibodies against microbial antigens in IBD
patients [61]. In experiments, GF mice were more susceptible
to colitis induced by dextran sodium sulfate (DSS) [22].
Recolonization ofGFmicewith feces from conventionalmice
reversed this phenotype, showing that microbiota plays a
beneficial role in colitis [22]. It is clear that dysbiosis results
in a lack of immune regulation and breakdown of tolerance
to commensal microorganisms. Dysbiosis allows outgrowth
of more pathogenic microorganisms and promotion of the
exacerbated inflammation underlying IBD [62]. Abnormal
gut colonization has been observed in subsets of Crohn’s
disease and ulcerative colitis patients [63]. Patients with
IBD, compared to healthy controls, have fewer bacteria
with anti-inflammatory properties and/ormore bacteria with
proinflammatory properties [64]. In addition, an abnormal
microbiota can cause IBD by expansion of colitogenic strains
that initiate development of colitis [65]. The molecular
mechanisms involved in the indirect effects of the microbiota
on the host intestine in inflammatory bowel disease are
described below.
The host develops a complex mucosal immune system
composed of epithelial and hematopoietic cells in order to
avoid ongoing inflammatory reactions to the microbiota and
preserve its ability to react to pathogenic insults. When such
interactions are perturbed, an exacerbated inflammation
occurs, leading to the development of IBD [55]. Recent
findings have focused on themolecularmechanisms involved
in the interaction between the gut microbiota and epithelium
cells [66–69] (Figure 2). The intestinal epithelium is more
than a single layer of cells working as a physical barrier; it has
developed mechanisms to protect itself from uncontrolled
inflammatory responses and to prevent bacterial dissemi-
nation to other organs. The epithelial responses against the
gut microbiota highlight the importance of a self-limiting
or noninflammatory cellular immune response scenario in
the antigen-rich intestinal environment.The reestablishment
of intestinal barrier integrity regulates the inflammatory
response in IBD [65, 68, 70]. GF mice recolonized with gut
microbiota have shown amarked reduction in inflammation.
The exacerbated response in colitis was related to a lack
of bacterial colonization of the gut that provides beneficial
effects in IBD [22]. Bacteria likely protect against IBD by
directly or indirectly enhancing the intestinal environment
via increased production of molecules such as SCFA by
beneficial bacteria. SCFAs, mainly acetate, propionate, and
butyrate, which are produced by bacteria of the Bacteroidetes
and Firmicutes phyla after fermentation of dietary fiber, show
anti-inflammatory properties in IBD [22, 71, 72]. Patients
with colitis and/or Crohn’s disease have reduced levels of
these bacteria in the colon [63]. The SCFAs carry out many
functions in the gut such as serving as fuel for the intestinal
epithelium cell, regulating gut epithelium cell proliferation,
differentiation, and gene expression, and initiating anti-
inflammatory effects on intestinal mucosa [22, 73–76].
Butyrate elicits biological effects on intestinal epithelial
cells by binding to GPR109A, a G protein-coupled receptor,
which is highly expressed in the colon [29]. Activation of
the GPR109A receptor by butyrate leads to a decrease in
intracellular levels of cAMP and this reduction controls
electrolyte and water absorption to reduce the incidence of
diarrhea in IBD [77]. SLC5A8, known as SMCT1 (sodium-
coupled monocarboxylate transporter 1), is a butyrate trans-
porter in a Na+-dependent electrogenic process and is highly
expressed in the colon. Butyrate has the ability to influence
gene expression in the colon through histone deacetylase
(HDAC) inhibition [78]. Interestingly, the expression of
SLC5A8 and GPR109A in the gut is influenced by bacteria
colonization. In the intestines of GF mice, the absence of
the microbiota and consequently the absence of SCFAs leads
to marked suppression of SLC5A8 and GPR109A expression
[79]. In contrast, colonization of GF mice leads to expression
of these genes to levels comparable to those of normal
conventional mice [80]. Thus, lack of expression of these
genes in GF mice could render them more susceptible to
developing experimental colitis and Crohn’s disease. Reduc-
tion in the intracellular availability of butyrate in colonocytes
may decrease its protective effects in IBD patients. Butyrate,
through a different mechanism, has also been shown to be
protective against colonic inflammation and colon cancer
[30]. Gpr109A, activated by butyrate, suppresses intestinal
inflammation by (1) induction of IL-18 secretion in colonic
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Figure 2: Schematic representation of a complexmucosal immune system composed of epithelial and hematopoietic cells that are able to react
to pathogenic insults. Development of IBD occurs mainly when epithelial cells are damaged and/or the intestinal microbiota composition is
not healthy.
epithelium, consequently inducing epithelium homeosta-
sis, and (2) promoting an anti-inflammatory response in
colonic macrophages and DCs that induce differentiation
of Tregs. CD4+Foxp3+ T regulatory cells are indispensable
for maintaining immune tolerance and are also an emerging
therapeutic target for IBD. Recent studies have demonstrated
that the metabolic products of certain bacterial strains in
the intestines attenuated disease in animal models of colitis
by inducing Treg proliferation [81–83]. These bacteria also
promoted their peripherical generation by inducing T cell
differentiation to Tregs through the generation of a TGF-𝛽-
rich environment [84].
The effects of SCFA may also result from its binding
to GPR41 and GPR43. Indeed, GPR41-deficient mice have a
higher susceptibility to experimental colitis, and this pheno-
type is associated with greater activation of NF-𝜅B (Nuclear
Factor kappa B). Activation of NF-𝜅B induces expression
of genes responsible for the production of proinflammatory
cytokines such as TNF and IL-8 that contribute to the
pathogenesis of IBD [85]. However, butyrate displays an anti-
inflammatory effect by decreasing expression of proinflam-
matory cytokines via inhibition of NF-𝜅B activation [86, 87].
A marked anti-inflammatory effect was observed by acetate
as well. The effects of acetate have been demonstrated by
Maslowski et al. to be due, in part, by the activation of GPR43
[22]. GPR43-deficient mice exhibit aggravated inflammation
related to exacerbated production of inflammatorymediators
and increased immune cell activation. Nevertheless, treat-
ment with acetate promotes resolution of intestinal inflam-
mation by GPR43 activation, thereby inducing apoptosis of
inflammatory cells in colitis [22]. Acetate treatment has also
been shown to reduce colonic inflammation in animalmodels
by promoting Treg differentiation [88].
A recent study highlighted the important role of acetate
production in preventing intestinal infection by its effect
on the maintenance of gut epithelial barrier function [66].
Intriguingly, acetate may affect the production of reactive
oxygen species (ROS) [22].Theproduction of ROS is involved
in a wide spectrum of biochemical processes. The ability of
ROS to activate an intracellular protein complex called the
inflammasome is of crucial importance in IBD [54, 78, 79].
The role of the inflammasome in modulating the innate
immune response in IBD is intimately related to the preser-
vation of epithelial barrier integrity and the maintenance of
gut homeostasis [50, 75]. Inflammasome complexes affect
the innate immune response through activation by pathogen
recognitionNLRs [76]. NLRP6 andNLPR3 are keymediators
of inflammasome complexes. NLRs activate caspase-1 and
drive proteolytic processing of proinflammatory cytokines
such as IL-1 and IL-18. These cytokines have evolved in
intestinal epithelial cells to avoid overactive inflammatory
responses against the host microbiota. Consequently, epithe-
lial barrier integrity induces tissue repair following injury [65,
89, 90]. Several groups, using a common acute and chronic
epithelial injury colitis mouse model based on the admin-
istration of DSS, reported an exacerbated disease severity
in mice deficient in caspase-1, NLRP3, and NLPR6. These
NLPRs are correlated with lower IL-1𝛽 and IL-18 produc-
tion during colitis [89–92]. Interestingly, NLPR6-deficient
mice have an altered gut microbiota (colitogenic bacteria),
which together with the exacerbated colitis phenotype can
be transferred to cohabitating WT mice. Therefore, NLRP6
participates in the steady-state regulation of the commen-
sal microbiota and appears to be essential for preventing
recurring colitis through the induction of basal secretion of
IL-18 by epithelial cells [65]. Therefore, the inflammasome
functions in the sensing of pathogens and the commensal
microbiota by not only nonhematopoietic cells, such as the
epithelial intestinal cells but also by hematopoietic cells [93].
Distinct inflammasome expression in different cell lineages
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may orchestrate different functions during mucosal inflam-
mation. They cooperate to maintain host tolerance towards
commensal microbes and to initiate a potent immune
response towards pathogens in the gut [94]. Nevertheless, the
factors inducing the formation of inflammasomes and the
precise effector mechanisms for regulation of the microbiota
and inflammatory response remain elusive. We do not yet
know whether SCFAs or GPCRs influence inflammasome
activation. However, the induction of ROS by SCFAs could
be a newmechanism by which microbial components trigger
inflammasome formation. Nevertheless, the inflammasome
regulates innate immune responses by sensing endogenous
and exogenous stimuli. Considering that the inflammasome
induces essential inflammatory responses in IBD, the sensing
of themicrobiota by the inflammasome through the action of
SCFAs could be a new protective mechanism associated with
microbiota metabolites. Furthermore, microbiota metabo-
lites can be considered analogous to microbe-associated
molecular patterns (MAMPs), which signal through GPCRs
to convey information about the microbiota and the host.
These receptors provide molecular mechanisms associated
with innate immunity that are involved in the recognition of
MAMPs as well as the classical innate immune receptors such
as TLRs and NLRs.
5. Obesity
Obesity has reached epic proportions, with incidence rates
above 20% in most western countries [95]. It is characterized
by abnormal or extensive fat accumulation that negatively
affects health. Such conditions lead to reduced life expectancy
and/or increased health complications such as heart disease,
type 2 diabetes, obstructive sleep apnea, certain types of
cancer, and osteoarthritis [96]. The development of obesity
is a complex process involving primarily a combination of
excessive food energy intake, lack of physical activity, and
genetic susceptibility. A few cases, however, are caused by
genes, endocrine disorders, slowmetabolism,medications, or
psychiatric illness [97]. The rise in incidence rates of obesity
can be attributed to the Western diet [98]. An imbalance in
the human gutmicrobiota has been associatedwithmetabolic
diseases including obesity, diabetes, and atherosclerosis [99].
Studies in both animals and humans have found fewer
Bacteroidetes and more Firmicutes colonizing the gut [99].
The first evidence of the role of the gut microbiota in
adiposity came from GF animal studies. Mice raised in
a conventional environment had more total body fat in
comparison to those raised under GF conditions. When GF
mice were conventionalized, they experienced a dramatic
increase in total body fat, and this increase was not associated
with differences in food consumption or decreased energy
expenditure [100]. The relation between gut microbiota and
obesity was also verified in knockout and diet-induced obese
mice. In such animal models, obesity was associated with
changes in the composition and metabolic function of the
microbiome [98]. Further evidence of the influence of the gut
microbiota on obesity is provided by brain-gut axis studies.
An increased intake of dietary fiber, which is fermented
in the colon, has been reported to decrease body weight
and glucose control. De Vadder and colleagues [101] have
shown that SCFAs activate intestinal gluconeogenesis via a
cAMP-dependent mechanism and a gut-brain neural circuit
involving the fatty acid receptor FFAR3. Frost and colleagues
[102] have demonstrated that colonic acetate crosses the
blood-brain barrier and is taken up by the brain. SCFAs is
also associatedwith activation of acetyl-CoA carboxylase and
changes in the expression profiles of regulatory neuropep-
tides that favor appetite suppression.
There are four main pathways that interfere with host
energy storage. These pathways involve intestinal epithelial
cells as sensors of microbial products and are believed
to influence how the gut microbiome regulates host gene
expression and affects energy expenditure and storage in
the host [98, 103] (Figure 3). Colonization of GF mice
with gut commensal bacteria alters the global intestinal
transcriptional response and the cellular origins of selected
responses by modulating the expression of genes involved
in several important intestinal functions. These functions
include nutrient absorption, mucosal barrier fortification,
xenobioticmetabolism, angiogenesis, and postnatal intestinal
maturation [103]. Studies using GF and conventionalized
mice also revealed that the microbiota promotes the absorp-
tion of monosaccharides from the gut lumen, resulting in
induction of de novo hepatic lipogenesis [104]. Fasting-
induced adipocyte factor (FIAF), a circulating lipoprotein
lipase inhibitor and member of the angiopoietin-like family
of proteins, is selectively suppressed by conventionalism
in the intestinal epithelium, liver, and adipose tissue of
normal mice. Using GF, conventionalized, normal, and FIAF
knockout mice, researchers established that FIAF suppres-
sion is essential for the microbiota-induced deposition of
triglycerides in adipocytes.Their findings suggest that the gut
microbiota is an important environmental factor that affects
energy harvest from food and energy storage in the host.
A second pathway that affects host energy storage
involves AMP-activated protein kinase (AMPK). AMPK is
activated in response tometabolic stresses, and this activation
results in an increased intracellular AMP to ATP ratio.
Backhed and colleagues [105] reported that in contrast to
mice with a gut microbiota, GF mice were protected against
developing obesity after consuming a high-fat, sugar-rich
Western diet. GF mice persistently remained lean despite
a high caloric intake. This phenotype is associated with
increased skeletal muscle and liver levels of phosphorylated
AMPK, which stimulate fatty acid oxidation in peripheral
tissues and lead to decreased glycogen content and increased
insulin sensitivity in the liver [97]. These results suggest
that the presence of a gut microbiota suppresses skeletal
muscle fatty acid oxidation through ametabolic pathway that
involves phosphorylation of AMPK. Moreover, GF knockout
mice lacking FIAF were not protected from diet-induced
obesity. GF FIAF−/−animals exhibited similar levels of phos-
phorylated AMPK compared to their wild-type littermates,
but they had reduced expression of genes encoding for the
peroxisomal proliferator-activated receptor coactivator Pgc-
1𝛼 and enzymes involved in fatty acid oxidation. Based
on these studies, GF mice are protected from diet-induced
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Figure 3: Effects of a high-fat diet. The altered microbial community of obese animals and humans promotes adiposity and decreased levels
of short chain fatty acids and influences metabolic processes such as storage and metabolism of lipids in adipose tissue, muscle, and liver.
obesity by two independent but complementary mechanisms
that result in increased fatty acid oxidation [98, 100, 105].
The host proteome has a limited number of glycoside
hydrolases that are able to break down complex plant polysac-
charides. The host microbiota synthesizes a large number
of these enzymes, allowing them to break down complex
carbohydrates into monosaccharides and SCFA. SCFAs dif-
fuse passively and are recovered via monocarboxylic acid
transporters, which also act as signaling molecules and
ligands for GPR41, GPR43, and GPR109. SCFAs can be used
as lipogenic substrates in host tissues but may promote fat
storage via the activation of GPR41 and GPR43 receptors [26,
103, 106, 107]. Moreover, the activation of GPR43 by acetate
and propionate contributes to the inhibition of lipolysis and
adipocyte differentiation, thereby promoting the expansion
of adipose tissue in animals fed a high-fat diet [108]. Because
the capacity to ferment carbohydrates to SCFA varies among
bacterial species (Bifidobacterium and Bacteroides species,
e.g., are known to produce SCFAs), the actual composition of
an individual’s intestinal microbiota may play an important
role in energy metabolism.
Finally, the low-grade inflammation and insulin resis-
tance observed in obesity can be triggered by alteration of the
gut barrier, leading to the higher plasma lipopolysaccharide
(LPS) levels observed in obese individuals. Such conditions
create a metabolic endotoxemia and drives obesity, insulin
resistance, and systemic inflammation [108, 109].
6. Conclusions
Microbial signaling is required for immune development and
homeostasis, whereas an intact immune system is neces-
sary for maintenance of a healthy gut microbiota. Evidence
presented herein suggests that some chronic inflammatory
diseases aremediated or affected by the dysfunction of the gut
microbiota and its metabolic products. Based on these obser-
vations,manipulation of intestinalmicrobiotamay prevent or
alleviate chronic inflammatory disease. The composition of
the microbiota can be manipulated by antibiotics, probiotics,
and dietary components. Probiotic consumption for the
maintenance of a healthy gut has been practiced for over a
century. In 1908, ElieMetchnikoffwon theNobel Prize for his
discovery that ingestion of Lactobacillus-containing yogurt
decreases the number of toxin-producing bacteria in the
intestine. Several clinical and animal studies have suggested
that probiotics and prebiotics can alleviate many inflam-
matory diseases such as asthma, obesity, and IBD. Clinical
trials have indicated that feeding L. rhamnosus GG and L.
fermentum tomothers during the prenatal and early postnatal
periods may be effective in the treatment and prevention of
early atopic disease in children. However, probiotics may not
have the same positive effect on all subjects or on all chronic
inflammatory diseases. One must also consider host dietary
habits and probiotic actions such as production of SCFAs and
direct DC activation. Additionally, many dietary components
directly influence probiotic survival and activity. A high-fiber
diet induces a healthy microbiota composition, leading to
increased SCFA production, which has anti-inflammatory
effects. Further studies are necessary to better understand the
mechanisms by which probiotics improve chronic diseases.
Additionally, probiotics could be genetically engineered to
have desirable anti-inflammatory properties.
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